Rescheduling Cannabis: What Are The Implications For MSOs, Tax Rule 280E, FDA And Pharma?
The potential of rescheduling and removing Tax Rule 280E could boost profits for U.S. businesses. However, Zuanic and Associates' latest report reveals complexities and overlooked consequences.